Joth Jacobson

Summary

Affiliation: Fred Hutchinson Cancer Research Center
Country: USA

Publications

  1. ncbi request reprint A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience
    Joth L Jacobson
    Southwest Oncology Group Statistical Center, Seattle, WA 98101 1468, USA
    Br J Haematol 122:441-50. 2003
  2. ncbi request reprint MDS-type abnormalities within myeloma signature karyotype (MM-MDS): only 13% 1-year survival despite tandem transplants
    Joth Jacobson
    Cancer Research and Biostatistics, Seattle, WA 98101 1468, USA
    Br J Haematol 122:430-40. 2003
  3. ncbi request reprint Partitioning and peeling for constructing prognostic groups
    Michael LeBlanc
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, MP 557, Seattle, WA 98109 1024, USA
    Stat Methods Med Res 11:247-74. 2002
  4. ncbi request reprint Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials
    Brian G M Durie
    Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    J Clin Oncol 22:1857-63. 2004
  5. ncbi request reprint Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II
    John Shaughnessy
    Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 120:44-52. 2003
  6. ncbi request reprint Treatment of multiple myeloma
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 103:20-32. 2004
  7. ncbi request reprint Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning
    Choon Kee Lee
    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Exp Hematol 31:73-80. 2003
  8. ncbi request reprint Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival
    Kai Da Wu
    Laboratory of Developmental Hematopoiesis, Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Blood 101:4982-9. 2003
  9. ncbi request reprint DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma
    Choon Kee Lee
    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Slot 776, 4301 West Markham, Little Rock, AR 72205, USA
    J Clin Oncol 21:2732-9. 2003
  10. ncbi request reprint Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival
    Maurizio Zangari
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, 72205, USA
    Clin Lymphoma 4:32-5. 2003

Detail Information

Publications13

  1. ncbi request reprint A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience
    Joth L Jacobson
    Southwest Oncology Group Statistical Center, Seattle, WA 98101 1468, USA
    Br J Haematol 122:441-50. 2003
    ..Additional evaluation in other MM patient populations is needed to confirm results...
  2. ncbi request reprint MDS-type abnormalities within myeloma signature karyotype (MM-MDS): only 13% 1-year survival despite tandem transplants
    Joth Jacobson
    Cancer Research and Biostatistics, Seattle, WA 98101 1468, USA
    Br J Haematol 122:430-40. 2003
    ....
  3. ncbi request reprint Partitioning and peeling for constructing prognostic groups
    Michael LeBlanc
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, MP 557, Seattle, WA 98109 1024, USA
    Stat Methods Med Res 11:247-74. 2002
    ..The peeling methods are relatively new and are developed in detail. Simulations and examples for describing groups of patients with poor outcomes using data from a clinical trial for patients with multiple myeloma are presented...
  4. ncbi request reprint Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials
    Brian G M Durie
    Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    J Clin Oncol 22:1857-63. 2004
    ..The purpose was to clarify the predictive value of specific levels of myeloma-associated monoclonal protein reduction and time to first progression using mature data sets...
  5. ncbi request reprint Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II
    John Shaughnessy
    Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 120:44-52. 2003
    ..02 and 0.1 respectively) and should be part of the initial work-up of patients with MM...
  6. ncbi request reprint Treatment of multiple myeloma
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 103:20-32. 2004
    ..Fundamental and clinical research should, therefore, focus on the molecular and biologic mechanisms of treatment failure in the high-risk subgroup...
  7. ncbi request reprint Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning
    Choon Kee Lee
    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Exp Hematol 31:73-80. 2003
    ..The aim of this study was to identify prognostic factors for outcome of high-risk patients with multiple myeloma after allogeneic transplantation prepared by reduced intensity conditioning (RIC)...
  8. ncbi request reprint Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival
    Kai Da Wu
    Laboratory of Developmental Hematopoiesis, Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Blood 101:4982-9. 2003
    ..004). The 2-year survival rate for patients with TA levels lower than 25% was 81%, and it was 52% in those with higher TA levels (P <.0001)...
  9. ncbi request reprint DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma
    Choon Kee Lee
    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Slot 776, 4301 West Markham, Little Rock, AR 72205, USA
    J Clin Oncol 21:2732-9. 2003
    ..To improve outcome in previously treated patients (at least two cycles of standard therapy) with multiple myeloma, thalidomide was combined with cytotoxic chemotherapy as induction therapy...
  10. ncbi request reprint Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival
    Maurizio Zangari
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, 72205, USA
    Clin Lymphoma 4:32-5. 2003
    ..002), and creatinine level > or = 2 mg/dL (P < 0.001). However, the development of DVT did not adversely affect survival when examined as a time-dependent variable and adjusted for standard risk features (hazard ratio, 0.8; P = 0.162)...
  11. ncbi request reprint Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression
    John Shaughnessy
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 101:3849-56. 2003
    ....
  12. ncbi request reprint Does leucovorin alter the intratumoral pharmacokinetics of 5-fluorouracil (5-FU)? A Southwest Oncology Group study
    Cary A Presant
    Los Angeles Oncologic Institute, St Vincent Medical Center, CA, USA
    Invest New Drugs 20:369-76. 2002
    ..The first 19F-MRS was following 5-FU 600 mg/m2 alone, and the second 19F-MRS was following by leucovorin 500 mg/m2 and then 5-FU 600 mg/m2...
  13. ncbi request reprint Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation
    Maurizio Zangari
    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, 4301 West Markham Street, Little Rock, AR 72205, USA
    Br J Haematol 126:715-21. 2004
    ..The rate of DVT recurrence observed in our study upon thalidomide resumption was sufficiently low to allow its continuation in patients who may benefit from this therapeutic intervention...